Should You Buy InnovAge Holding Corp. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, InnovAge Holding Corp. (INNV) carries a solid Quality of Company rating of 6.8/10. Trading at $10.92, our multi-model framework evaluates whether the company's financial profile offers a favorable risk-reward setup.
The short answer: 0 of 9 CirclFi valuation models project upside for InnovAge Holding Corp. (INNV) at $10.92 — the model consensus leans bearish, with a Quality Score of 6.8/10 and Value-Trap risk of 19/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for InnovAge Holding Corp. (INNV) in 2026?
What Is the Bull Case vs the Bear Case for InnovAge Holding Corp. (INNV)?
| Bull case | Bear case — $0.13 target (-98.8%) |
|---|---|
| No active model projects meaningful upside for INNV at $10.92. Bulls would have to argue that qualitative factors the models cannot measure will unlock value. | According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model sees the stock as overvalued with a fair value of $0.13 (-98.8%), suggesting that the market price embeds overly optimistic growth assumptions. |
| According to the CirclFi Deep Alpha Valuation Engine, model disagreement is high with a +91.1% spread between the most bullish and bearish models, signaling elevated analytical uncertainty. |
How Does INNV Compare to Its Medical Care Facilities Peers?
Valuation data pages: DCGO · AMN · CYH · CCEL · ASTH · AVAH · STLN · FCHS · HCA · ADUS · NHC
Which Other Stocks Score Like INNV on Quality?
Closest companies to INNV’s Quality of Company score of 6.8/10, across all industries.
- RXO — RXO, Inc. (QOC 6.8) · analysis
- MB — MasterBeef Group (QOC 6.8) · analysis
- PHI — PLDT Inc. (QOC 6.8) · analysis
- CSBR — Champions Oncology, Inc. (QOC 6.8) · analysis
- VNDA — Vanda Pharmaceuticals Inc. (QOC 6.8) · analysis
- NREF — NexPoint Real Estate Finance, Inc. (QOC 6.8) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
Which Medical Care Facilities Screens Does INNV Appear In?
So Is InnovAge Holding Corp. (INNV) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on InnovAge Holding Corp. at $10.92. 9/9 models flag overvaluation, median fair value sits at $3.17 (-70.9%), and the risk-reward profile appears unfavorable. Quality at 6.8/10 adds to the concern. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. InnovAge Holding Corp.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About INNV Stock?
Should I buy INNV stock right now?
Based on CirclFi's multi-model analysis, 0 of 9 models see upside for INNV at $10.92. No active models currently project upside, suggesting the market price may already reflect or exceed fair value. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in InnovAge Holding Corp.?
Key risks include: wide model disagreement (7919% spread), signaling high uncertainty; general market and sector-specific risks affecting Medical Care Facilities companies. Always diversify and consult a financial advisor.
How does INNV compare to its competitors?
Among Medical Care Facilities peers, INNV holds a Quality Score of 6.8/10. Comparable companies include DCGO (QOC 6.8), AMN (QOC 6.7), CYH (QOC 7.1). The relative ranking helps investors identify whether INNV offers better fundamental quality than alternatives in the same sector.
Is INNV a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. INNV's Quality Score of 6.8/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy INNV at?
CirclFi does not provide target buy prices or price alerts. However, our 9 active models produce fair value estimates ranging from $0.13 to $10.08. At $10.92, the stock trades above all model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for INNV.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad